This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Feihe International Announces Its Recent R&D Achievements

Stocks in this article: ADY

BEIJING and LOS ANGELES, Sept. 26, 2011 /PRNewswire Asia-FirstCall/ -- Feihe International, Inc. (NYSE: ADY; "Feihe International" or the "Company") (formerly known as American Dairy, Inc.), one of the leading producers and distributors of premium infant formula, milk powder and soybean, rice and walnut products in China, today announced its recent R&D achievements, including its participation in the Program of China's 12th Five-Year Plan for National Economic and Social Development ("The 12th Five-Year Plan") and the completion of clinical trial feeding tests for its super premium brand of infant formula, AstroBaby.

The 12th Five-Year Plan is an important statement of national policy that guides the direction and objectives of China's economic and social development for the coming five years.  It is a blueprint for governmental planning in key sectors from 2011 to 2015.

Mr. Leng You Bin, the Company's Chairman and Chief Executive Officer, stated, "We are extremely pleased to announce that we are one of the first companies hosting the program, a privilege provided by China's Ministry of Science and Technology.  The Company will focus on research and technology issues relating to the processing of milk-based products and will also conduct research and analyze key infant formula ingredients, including breast milk, and China's infant formula market. Feihe is the only dairy company participating in this exclusive program and we are honored to have been chosen.  In addition, our super premium infant formula, AstroBaby, a high-end infant formula designed to meet the nutritional needs of infants during their most crucial development period, completed clinical trials.  AstroBaby was successfully introduced in 2010 and by the second quarter of 2011, sales increased to approximately 2% of the Company's total infant formula sales.  As a result of the Company's performance and accomplishments, the Department of Science and Technology of Heilongjiang Province provided a 5 million RMB grant."

The clinical trials are performed by governmental agencies and measure growth and behavioral development, and other indicators for 150 babies with a testing period of 90 days.  The clinical trials are voluntary research and fully compliant with safety and ethical standards.  The clinical trial feeding test results indicate that, of the infant formula tested, AstroBaby was closest to breast milk in terms of babies' physical growth, digestive systems, language and personal social development.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs